Albanese denies US rift, calls for war de-escalation
Anthony Albanese denies a US-Australia rift while seeking clarity from President Trump on Iran war objectives and calling for global economic de-escalation.
Heidi Cuthbert
CEO & FounderFounder and CEO of Grafa, leading the company's vision to democratise financial data and empower investors with innovative tools.
Contact
Contact editorial teamArticles by Heidi Cuthbert
West African Resources flags record gold production
West African Resources (ASX:WAF) is forecasting record gold production for 2026 as it transitions into a multi-asset producer.
Scienture revenue rallies 216% in 2025 on Arbli launch and record margin expansion
Scienture (NASDAQ:SCNX), a specialty pharmaceutical company focused on developing and commercializing innovative therapies for underserved patient populations, today reported its financial results for the full year ended December 31, 2025.
Rio Tinto maintains guidance despite cyclone disruptions
Mining giant Rio Tinto (ASX:RIO) has reaffirmed its full-year shipment guidance for its Pilbara iron ore operations.
Greatland Resources' Telfer gold resource jumps 150%
Greatland Resources (ASX:GGP) announced a150% increase to its Telfer gold resource, which now stands at 8 million ounces.
Oil and Gas
Fuel excise in Australia halved to ease cost of living
Prime Minister Anthony Albanese announced a temporary 50% reduction in the fuel excise.
EML Payments appoints Adam Olding as Global CEO
EML Payments (ASX:EML) appointed Adam Olding as its new Global CEO, effective immediately.
IGO consolidates Copper Wolf Project ownership
IGO (ASX:IGO) announced the ownership consolidation of the Copper Wolf Project from Buxton Resources (ASX:BUX).
Technology
Ainos reports 499% revenue growth & AI Nose expansion
Ainos (NASDAQ:AIMD) reported a pivotal fiscal year 2025, characterized by a roughly 499% surge in revenue and a successful transition into high-volume industrial markets.
Health
Veradermics reports FY 2025 results and post-IPO cash runway through 2029
Veradermics (NYSE:MANE), a late-clinical stage biopharmaceutical firm specializing in aesthetic and dermatological therapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.